EnteroMedics shares surged Wednesday, a day after the medical device company said Methodist Dallas Medical Center successfully completed its first implant of the company’s vBloc Neurometabolic Therapy through the Veterans Choice Program. Shares rose 14.7% to $4.99 at 9:37 a.m. in New York after touching $5.20.
vBloc Therapy works to control sensations of hunger using a pacemaker-like device that is implanted under the skin during a safe, minimally invasive procedure. The vBloc System gives the patient a sensation of fullness, empowering them to eat less, control their appetite, and lose weight. Studies have shown that vBloc Therapy produces meaningful weight loss while also reducing comorbidity factors related to obesity.